Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Rhea-AI Summary

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that it will provide a company overview and updates at the Canaccord Genuity Annual Growth Conference in Boston, Massachusetts, from August 8-11, 2022. The presentation is scheduled for August 10 at 4:30 p.m. E.T. and will be webcasted, with a link available on the Oramed website 48 hours prior. Oramed focuses on oral drug delivery systems and aims to revolutionize diabetes treatment with its lead candidate, ORMD-0801, currently in pivotal Phase 3 studies.

News Market Reaction – ORMP

+5.61%

+5.61% Session move

In the trading session that priced this news, ORMP gained 5.61%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, July 11, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-person company overview and share the Company's latest updates at the Canaccord Genuity Annual Growth Conference, to be held in Boston, Massachusetts from August 8-11, 2022.

Presentation Details:

Canaccord Genuity Annual Growth Conference

Date:               Wednesday, August 10, 2022

Time:               4:30 p.m. E.T.

Location:         InterContinental Boston Hotel, 510 Atlantic Avenue, Boston, Massachusetts

The presentation will be webcasted. The link to view the presentation will be uploaded to the Oramed website (www.oramed.com) 48 hours before the event and will be available for 90 days following the presentation.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule.

For more information, please visit www.oramed.com

Company Contact
Zach Herschfus 
+1-844-9-ORAMED 
zach@oramed.com 

Logo - https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/oramed-to-present-at-the-upcoming-canaccord-genuity-annual-growth-conference-301583656.html

SOURCE Oramed Pharmaceuticals Inc.

FAQ

When is Oramed Pharmaceuticals presenting at the Canaccord Genuity Annual Growth Conference?

Oramed Pharmaceuticals will present on August 10, 2022, at 4:30 p.m. E.T.

Where is the Canaccord Genuity Annual Growth Conference taking place?

The conference is being held in Boston, Massachusetts.

What is Oramed's lead candidate for diabetes treatment?

Oramed's lead candidate is ORMD-0801, which is being evaluated in two pivotal Phase 3 studies.

How can I view Oramed's presentation at the conference?

The presentation will be webcasted, and a link will be available on Oramed's website 48 hours before the event.

What is the focus of Oramed Pharmaceuticals?

Oramed Pharmaceuticals focuses on developing oral drug delivery systems, particularly for diabetes treatment.